Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04189614 · ClinicalTrials.gov registry record · Phase 1
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
A Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT04189614: Active Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC), sponsored by AbbVie.
NCT04189614 is a Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 65 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04189614, a Phase 1 study of Cancer and Non-small Cell Lung Cancer (NSCLC), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Primary Outcome
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).
Conditions Studied
Interventions
- DRUG Cofetuzumab Pelidotin
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center /ID# 216433 - Miami
- Moffitt Cancer Center /ID# 215101 - Tampa
Texas
- Oncology Consultants /ID# 215932 - Houston
- University of Texas MD Anderson Cancer Center /ID# 215876 - Houston
Other
- Rambam Health Care Campus /ID# 217536 - Haifa
- Rabin Medical Center /ID# 217537 - Petah Tikva
Seoul Teugbyeolsi
- Asan Medical Center /ID# 222280 - Seoul
- Samsung Medical Center /ID# 222906 - Seoul
Alabama
- University of Alabama at Birmingham - Main /ID# 213605 - Birmingham
Arkansas
- Highlands Oncology Group, PA /ID# 215383 - Springdale
California
- Duplicate_Stanford University School of Med /ID# 213450 - Stanford
Colorado
- Univ of Colorado Cancer Center /ID# 215295 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT04189614 still lists
NCT04189614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cofetuzumab Pelidotin is the first listed.
NCT04189614 names 20 study sites across 16 states, led by Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT04189614 about?
NCT04189614 is a clinical study titled "An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer". This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
What is the current status of trial NCT04189614?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2020-02-13. Estimated completion is 2025-12.
What conditions does trial NCT04189614 study?
This clinical trial studies the following conditions: Cancer, Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT04189614?
The interventions under investigation include: Cofetuzumab Pelidotin (DRUG).
Who is sponsoring clinical trial NCT04189614?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04189614 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04189614's enrollment target sits among peer trials
65 386th of 615 higher than 229 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI